NRSN
NASDAQ · Biotechnology
Neurosense Therapeutics Ltd
$0.78
+0.03 (+3.42%)
Open$0.82
Previous Close$0.76
Day High$0.82
Day Low$0.77
52W High$2.60
52W Low$0.63
Volume—
Avg Volume274.8K
Market Cap22.87M
P/E Ratio—
EPS$-0.85
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+4,412.0% upside
Current
$0.78
$0.78
Target
$35.23
$35.23
$27.84
$35.23 avg
$57.14
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.58M | 1.62M | 1.28M |
| Net Income | 134.3K | 163.7K | 131.8K |
| Profit Margin | 8.5% | 10.1% | 10.3% |
| EBITDA | 233.3K | 224.5K | 177.5K |
| Free Cash Flow | 149.0K | 201.8K | 175.9K |
| Rev Growth | +15.5% | +19.0% | +13.7% |
| Debt/Equity | 0.19 | 0.18 | 0.19 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |